Innova Biosciences Ltds core business is bioconjugation (antibody labeling) the joining of two molecules to form a hybrid conjugate™. Conjugates are used in hospital and research labs around the world; they also feature in consumer items such as pregnancy test kits (the conjugate is responsible for the blue line). Innova™s one-step conjugation method (Lightning-Link) massively simplifies the production of conjugates that are needed for research and immunodiagnostic applications. Innova also offers exclusive services for optimizing the performance of conjugates and developing more sensitive immunodiagnostic tests. Innova also sells several niche products to pharmaceutical research and development labs.
Mr Tom Speedy
Integrity Life Sciences
Providing Business Services and Consultancy to the Health Care and Life Sciences sectors.
Predominantly working with smaller biotech/pharma companies (including academic spin outs) and smaller health care charities.
Dr William Watson
NextPharma Technologies is a world class outsourcing partner to the pharmaceutical and biotechnology industries.
We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing of New Chemical Entities (NCEs) and generic products. NextPharma is a world leader in pellet technologies and in specialist product manufacturing including hormones, penicillins, cephalosporins and controlled drugs. We are experts in paediatric drug formulation, development and manufacture. In addition to these specialist areas we have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.
NextPharma offers ‘one-stop’ logistics solutions tailored to meet the needs of the global pharmaceutical industry under the rigid standards of cGSP/GDP regulations.
NextPharma operates globally with six product development centres, six manufacturing plants and seven temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan. We employ 1,000 people dedicated to serving over 200 customers world wide and a customer base, which includes many of the world’s leading pharmaceutical, specialty pharma and biotechnology companies.
All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.
Mr Andrew LewinVice President Business Development Europe PDS
Mr David Sykes
Oxford Expression Technologies
OET Ltd is a biotechnology company and centre of excellence for baculovirus based recombinant protein expression. OET provides protein expression products, services, consultancy and training to pharmaceutical and biotech companies and academic institutions. OET is also carrying out an extensive R&D programme.
Dr Richard BroadheadSales & Marketing Manager
Penn services include: CMC Consultancy, Formulation Development, Analytical Development, Clinical Trial Supply, Contract Manufacturing, Qualified Persons Release Services, Paediatrics Formulation and Manufacturing, Hi-Potency capabilities, Orphan drug expertise, More than 30 Years of specials, manufacturing expertise, Comparator Sourcing.
The above offerings are all under one roof providing a strong and easy communication channel between departments making developments, manufacturing and analytical processes.
Mr Michael Kruidenier
Mr David Spillett
prmaconsulting offers best-in-class strategic and operational Pricing & Reimbursement, Market Access and Health Economics advice. We work for the majority of the top 15 Big Pharma companies, as well as in Biotech and Medtech.
Mr Mark Larkin
Ms Clare Jones
Q Chip is using a novel approach to encapsulate therapeutic peptides in bioresorbable polymer microspheres for injection and sustained drug release (SR). We avoid the use of harsh solvents, high temperatures and shearing forces and achieve high API loading and microsphere monodispersity- two of the most important desirable features of any encapsulation approach, minimising production cost and enhancing syringe-ability, with controllable burst release. We have recently demonstrated successful sustained release over one month of octreotide, in a preclinical model. A small initial burst release was seen, followed by sustained and essentially zero order octreotide release over at least 35 days. Interestingly, there was no lag phase of octreotide release which might otherwise mandate additional daily injections to achieve therapeutic dosing.
We have had similar success with one and three month SR formulations of leuprolide and intend to go next to POC in man. Our octreotide and leuprolide SR formulations are available for licensing.
We use a similar benign approach to therapeutic protein encapsulation and are collaborating with Artes GmbH on the encapsulation of interferon alpha 2a for SR - targeting an improvement on the weekly shots of pegylated interferon currently taken by hep C sufferers.
Q Chip is developing novel technology platforms for the encapsulation of therapeutic peptides for sustained release (SR) and is committed to demonstrating its platforms' capabilities by producing POC data on SR depot formulations of two market leading therapeutic peptides, leuprolide and octreotide. These depot products will compete in the oncology market and in Q Chip's view represent de-risked opportunities for potential partners since both should be amenable to abbreviated regulatory procedures. We are willing to consider licensing our leuprolide and octreotide formulations and we are also interested in talking to potential partners with peptides in development - there is a clear opportunity to develop new sustained release formulations that may extend product patent life as well as enhancing patient compliance.
Dr Cora GriffinBusiness Development Manager
Saccharides Science and Technology
Through the novel application of gap analysis methods in disease biotechnology, SST develops medications that serve as biochemical prostheses that bridge broken reaction pathways, create a normal physiological environment and programme the body to build a natural resistance to the disease. Unlike conventional treatments that act to directly suppress diseases rapidly often with adverse side- effects, SST’s products are designed to gradually correct genetic faults and biochemical mistakes that underlie these diseases.
SST has been developing a series of patented pharmaceutical and medical device technologies and has found commercial success in its product, Amzylite F1.2, the first of its many upcoming diabetic oral medications.